Skip to main content

Table 3 Contraindications to carbapenem sparing agents

From: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Antimicrobial

Total

Rash

Anaphylaxis

SCAR

Pregnancy

Heart failurea

Cirrhosis

Non-urinary tract source

Renal impairmente

Ceftolozane-tazobactam

2

1

1

0

–

–

–

–

–

Ceftazidime-avibactam

2

1

1

0

0

–

–

–

–

Plazomicinb

42

0

0

0

0

–

–

26

21

Fosfomycinc

32

0

0

0

–

4

3

25

1

Cefiderocold

26

1

1

0

0

–

–

26

–

  1. SCAR severe cutaneous adverse reaction
  2. Excludes cases which tested resistant in vitro
  3. a Includes both acute decompensated heart failure and NYHA IV heart failure
  4. b 5 patients had both non-urinary tract source and renal impairment (eGFR < 30 mL/min/1.73 m2) as contraindications
  5. c 1 patient had both cirrhosis and was dialysis dependent
  6. d 2 patients had both allergy and non-urinary tract source
  7. e Dialysis dependence for fosfomycin and eGFR < 30 mL/min/1.73 m2 for plazomicin
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us